Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.

Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Trojanowski JQ.

J Neurosci. 2010 Oct 13;30(41):13861-6. doi: 10.1523/JNEUROSCI.3059-10.2010.

2.

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.

Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Brunden KR.

J Neurosci. 2012 Mar 14;32(11):3601-11. doi: 10.1523/JNEUROSCI.4922-11.2012.

3.

Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.

Brunden KR, Ballatore C, Lee VM, Smith AB 3rd, Trojanowski JQ.

Biochem Soc Trans. 2012 Aug;40(4):661-6. doi: 10.1042/BST20120010. Review.

4.

Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH, Cadelina GW, Decarr LB, Yang L, Liu V, Fessler C, Protassio J, Riff T, Turner H, Janus CG, Sankaranarayanan S, Polson C, Meredith JE, Gray G, Hanna A, Olson RE, Kim SH, Vite GD, Lee FY, Albright CF.

J Neurosci. 2012 May 23;32(21):7137-45. doi: 10.1523/JNEUROSCI.0188-12.2012.

5.

The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.

Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, Hogan AM, Trojanowski JQ, Smith AB 3rd, Lee VM.

Pharmacol Res. 2011 Apr;63(4):341-51. doi: 10.1016/j.phrs.2010.12.002. Epub 2010 Dec 14.

6.

Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy.

Makani V, Zhang B, Han H, Yao Y, Lassalas P, Lou K, Paterson I, Lee VM, Trojanowski JQ, Ballatore C, Smith AB 3rd, Brunden KR.

Acta Neuropathol Commun. 2016 Sep 29;4(1):106.

7.

HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.

Xiong Y, Zhao K, Wu J, Xu Z, Jin S, Zhang YQ.

Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4604-9. doi: 10.1073/pnas.1207586110. Epub 2013 Mar 4.

8.

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.

Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ.

Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):227-31. Epub 2004 Dec 22.

9.

Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.

Kovalevich J, Cornec AS, Yao Y, James M, Crowe A, Lee VM, Trojanowski JQ, Smith AB 3rd, Ballatore C, Brunden KR.

J Pharmacol Exp Ther. 2016 May;357(2):432-50. doi: 10.1124/jpet.115.231175. Epub 2016 Mar 15.

10.

Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

Ballatore C, Brunden KR, Huryn DM, Trojanowski JQ, Lee VM, Smith AB 3rd.

J Med Chem. 2012 Nov 8;55(21):8979-96. doi: 10.1021/jm301079z. Epub 2012 Sep 28. Review.

11.

The microtubule-stabilizing drug Epothilone D increases axonal sprouting following transection injury in vitro.

Brizuela M, Blizzard CA, Chuckowree JA, Dawkins E, Gasperini RJ, Young KM, Dickson TC.

Mol Cell Neurosci. 2015 May;66(Pt B):129-40. doi: 10.1016/j.mcn.2015.02.006. Epub 2015 Feb 12.

PMID:
25684676
12.

Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.

Ballatore C, Brunden KR, Trojanowski JQ, Lee VM, Smith AB 3rd, Huryn DM.

Curr Top Med Chem. 2011;11(3):317-30. Review.

13.

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.

Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007. Epub 2008 Mar 21.

PMID:
18490011
14.

MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.

Brunden KR, Gardner NM, James MJ, Yao Y, Trojanowski JQ, Lee VM, Paterson I, Ballatore C, Smith AB 3rd.

ACS Med Chem Lett. 2013 Jul 23;4(9):886-9. doi: 10.1021/ml400233e. eCollection 2013 Sep 12.

15.

A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.

Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS.

J Pharmacol Exp Ther. 2008 Apr;325(1):146-53. doi: 10.1124/jpet.107.130526. Epub 2008 Jan 16.

16.

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models.

Melis V, Magbagbeolu M, Rickard JE, Horsley D, Davidson K, Harrington KA, Goatman K, Goatman EA, Deiana S, Close SP, Zabke C, Stamer K, Dietze S, Schwab K, Storey JM, Harrington CR, Wischik CM, Theuring F, Riedel G.

Behav Pharmacol. 2015 Jun;26(4):353-68. doi: 10.1097/FBP.0000000000000133.

17.

Tau and axonopathy in neurodegenerative disorders.

Higuchi M, Lee VM, Trojanowski JQ.

Neuromolecular Med. 2002;2(2):131-50. Review.

PMID:
12428808
18.

Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo.

Planel E, Krishnamurthy P, Miyasaka T, Liu L, Herman M, Kumar A, Bretteville A, Figueroa HY, Yu WH, Whittington RA, Davies P, Takashima A, Nixon RA, Duff KE.

J Neurosci. 2008 Nov 26;28(48):12798-807. doi: 10.1523/JNEUROSCI.4101-08.2008.

19.

Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.

Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW.

J Neurocytol. 2003 Nov;32(9):1091-105.

PMID:
15044841
20.

Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy.

Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM.

J Neurosci. 2013 Jan 16;33(3):1024-37. doi: 10.1523/JNEUROSCI.2642-12.2013.

Supplemental Content

Support Center